Pages that link to "Q29617910"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials (Q29617910):
Displaying 50 items.
- Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial (Q21089697) (← links)
- RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist (Q21132391) (← links)
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary (Q22241786) (← links)
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Q22241919) (← links)
- 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Q22241922) (← links)
- Statins for acute coronary syndrome (Q24193862) (← links)
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis (Q24194514) (← links)
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients (Q24200984) (← links)
- Statins for the primary prevention of cardiovascular disease (Q24201513) (← links)
- Statins for the primary prevention of cardiovascular disease (Q24234813) (← links)
- Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia (Q24235790) (← links)
- Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses (Q24289205) (← links)
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial (Q24569666) (← links)
- C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study (Q24617734) (← links)
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (Q24619410) (← links)
- Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk (Q24626884) (← links)
- Are statins diabetogenic? (Q24630205) (← links)
- 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial (Q24630312) (← links)
- Imaging of coronary atherosclerosis in various susceptible groups (Q26738569) (← links)
- Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies (Q26738588) (← links)
- Statin-induced diabetes: incidence, mechanisms, and implications (Q26740677) (← links)
- Unmet Needs in LDL-C Lowering: When Statins Won't Do! (Q26741705) (← links)
- Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies (Q26746907) (← links)
- A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality (Q26747195) (← links)
- Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction (Q26747475) (← links)
- PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab (Q26747776) (← links)
- Statin non-adherence: clinical consequences and proposed solutions (Q26748560) (← links)
- The relationship between Lp(a) and CVD outcomes: a systematic review (Q26749317) (← links)
- Lipids in liver transplant recipients (Q26750468) (← links)
- Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill (Q26753102) (← links)
- 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension (Q26764784) (← links)
- Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens (Q26766157) (← links)
- The metabolic vascular syndrome - guide to an individualized treatment (Q26767142) (← links)
- The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy (Q26771168) (← links)
- Single-nucleotide polymorphisms: a perspective of cardiovascular prevention (Q26776025) (← links)
- Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials (Q26776293) (← links)
- Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain (Q26779403) (← links)
- LDL cholesterol, statins and PCSK 9 inhibitors (Q26782522) (← links)
- Use of statins and the incidence of type 2 diabetes mellitus (Q26783136) (← links)
- Statins: Cholesterol guidelines and Indian perspective (Q26783226) (← links)
- Statins for primary cardiovascular prevention in the elderly (Q26783401) (← links)
- PCSK9 inhibition: the way forward in the treatment of dyslipidemia (Q26784482) (← links)
- Statin use in prediabetic patients: rationale and results to date (Q26786008) (← links)
- The effect of statins on average survival in randomised trials, an analysis of end point postponement (Q26786733) (← links)
- Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials (Q26797486) (← links)
- Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway (Q26800894) (← links)
- Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL (Q26801507) (← links)
- Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies (Q26823037) (← links)
- Toward individualized cholesterol-lowering treatment in end-stage renal disease (Q26823146) (← links)
- Novel therapies focused on the high-density lipoprotein particle (Q26823249) (← links)